Key Takeaways
- Hikma's (LSE:HIK) H1 2026 group Revenue rose 4% to $1.73 billion, with core operating profit climbing 9% to $405 million.
- The Branded division, focused on the Middle East and North Africa, drove growth with revenue up 15% to $502 million, while US injectables revenue was flat.
- The Interim Dividend was lifted 6% to 38 cents per share, supported by an active $250 million buyback, even as net Debt rose to $1,694 million.
- Injectables' US revenue fell around 4% as customers transitioned from Vanco Ready to the newly launched Tyzavan, with roughly 80% of eligible customers already switched.
- Management reiterated full-year guidance, with Branded now tracking at the top end of its guided growth range.
Hikma Pharmaceuticals (LSE:HIK), the London-listed generics-to-injectables group with deep roots in the Middle East, delivered a first half its chief executive called "solid" rather than spectacular. Group revenue rose 4% to $1.73 billion and core operating profit climbed 9% to $405 million in the six months to 30 June 2026, figures released on 6 August. The headline growth masks a more uneven picture, with the Branded division roaring ahead while the US injectables Business worked through a bumpy product transition.
What Happened
On 6 August 2026, Hikma reported H1 revenue of $1,728 million, up 4% on the $1,658 million booked a year earlier, and core operating profit of $405 million, up 9% from $373 million. Core Operating Margin expanded to 23.4%. Core profit attributable to shareholders rose a more modest 3% to $277 million, while core Earnings Per Share increased 5% to 128 cents. The board lifted the interim dividend 6% to 38 cents. Chief executive Said Darwazah said Hikma was "delivering against the commitments we have made," reiterating full-year guidance.
The results were driven overwhelmingly by Branded, Hikma's MENA-focused specialty and chronic-disease business, where revenue jumped 15% to $502 million and core operating profit rose 23%. Injectables revenue was flat at $685 million as the US business absorbed the transition from Vanco Ready to the newly launched Tyzavan, while Hikma Rx (the renamed generics division) held revenue broadly flat at $520 million but grew core operating profit 16% on an improved mix and renegotiated sodium oxybate terms.
Why It Matters
Hikma occupies an unusual niche among UK-listed pharma names: it is simultaneously one of the largest suppliers of generic medicines in the United States, the biggest pharmaceutical company in MENA, and the fourth-largest injectables player in Europe. That spread has historically smoothed Volatility in any single market, but it also means tracking three quite different growth stories at once. The H1 results show Diversification working in one direction — Branded's strength offsetting Injectables' softness — while raising the question of how durable the US injectables recovery will be once Tyzavan is fully embedded with customers.
For income investors, the dividend increase and active $250 million buyback signal confidence in cash generation, even as net debt has risen. For growth investors, the acceleration in Branded — now running at the top end of its guided range — is the more interesting story, given it carries Hikma's highest margins.
Latest Financial and Operational Performance
Operating Cash Flow rose 33% to $214 million, and core EBITDA increased 8% to $463 million. Net debt stood at $1,694 million at the half-year, up from $1,387 million at end-2025, pushing net debt to core EBITDA to 1.9 times from 1.6 times, largely reflecting the buyback and Working Capital movements.
Injectables' US revenue fell around 4% as customers worked through existing Vanco Ready stock before adopting Tyzavan, launched in December 2025; management said roughly 80% of eligible customers had already transitioned. Europe and MENA sales partly offset the US dip, but divisional core operating profit fell 8% to $189 million, with margin easing to 27.6%. Hikma Rx's operating margin expanded to 20.6% on the sodium oxybate renegotiation and mix gains. Branded's core operating margin reached 32.5%, the group's highest, powered by Saudi Arabia growth and first-to-market and first-generic launches.
Key Numbers
- Group revenue: $1,728m, up 4% (H1 2026 vs H1 2025)
- Core operating profit: $405m, up 9%; core operating margin 23.4%
- Core profit attributable to shareholders: $277m, up 3%; core EPS 128 cents, up 5%
- Branded revenue: $502m, up 15% (up 14% constant currency); core operating profit up 23%
- Injectables revenue: $685m, flat; core operating profit $189m, down 8%
- Hikma Rx revenue: $520m, broadly flat; core operating profit $107m, up 16%
- Interim dividend: 38 cents per share, up 6%
- Net debt: $1,694m, up from $1,387m at 31 December 2025; net debt/core EBITDA 1.9x
Growth Opportunities
Hikma is leaning on Branded as its growth engine, guiding to revenue growth at the top of its 6–8% range for the year, supported by chronic therapies including diabetes treatments and expansion into immunology and gastroenterology. The division continues signing in-licensing partnerships — ten new agreements in H1 alone — and bringing first-generic launches to market ahead of local rivals.
In Injectables, management expects momentum through H2 as Tyzavan adoption completes and prescription volumes convert into reported sales; the company has lifted US sales and Marketing Investment by 10%. Hikma Rx is positioning for the longer term through contract Manufacturing , targeting 20% of divisional revenue by 2030, alongside a Biosimilars push in MENA. Group-wide, R&D spending rose 18% to around 5% of revenue, funding a pipeline of over 330 products, including a newly signed co-development deal for a generic version of GSK's Ellipta inhaler technology.
Risks Investors Should Know
Generic competition remains the most immediate pressure point: management flagged that rivalry around sodium oxybate should intensify through the second half, and the base US generics business continues to see modest price erosion. Hikma also faces the overhang of potential US tariffs on imported medicines, though it argues its Ohio and New Jersey manufacturing base leaves it comparatively well placed. Regional conflict in the Middle East has delayed some Branded marketing activities and tender timings, with the company citing "limited" but real cost impacts from shipping, insurance and fuel disruption. Net debt has risen alongside the buyback, and the fall in Injectables operating profit shows how dependent that division remains on a single product transition going smoothly.
What to Watch Next
Investors should watch second-half Injectables revenue for confirmation the Tyzavan transition has completed and reported sales are catching up with prescription volumes. Branded's ability to sustain double-digit growth against tougher regional conditions, buyback progress, and any update on US Tariff policy affecting generics imports are the other near-term catalysts ahead of full-year results.
Outlook
Hikma's first half confirms genuine momentum in its highest-margin business but a reminder that its US injectables Franchise , while structurally attractive, remains exposed to product-transition timing. With guidance reiterated and Branded tracking ahead of plan, the second half will show whether Injectables can close the gap and turn a solid half into a fuller-year turnaround.






Please wait processing your request...